Nuvectis Pharma (NASDAQ:NVCT) Shares Gap Up – What’s Next?Defense World · Oct 12, 2026
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026GlobeNewsWire · Oct 9, 2026
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock Has Consensus Target Price of $36.25 According to BrokeragesDefense World · Sep 29, 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade GliomaGlobeNewsWire · Sep 24, 2026
BlackRock Inc. Acquires New Stake in Nuvectis Pharma, Inc. $NVCTDefense World · Sep 4, 2026
Nuvectis Pharma To Participate in Upcoming Investor ConferencesGlobeNewsWire · Sep 3, 2026Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.26 | -$0.30 | Miss |
| May 5, 2026 | -$0.30 | -$0.26 | Beat |
| Feb 11, 2026 | -$0.26 | -$0.31 | Miss |
| Nov 4, 2025 | -$0.24 | -$0.44 | Miss |
| Aug 5, 2025 | -$0.25 | -$0.30 | Miss |
| May 6, 2025 | -$0.30 | -$0.27 | Beat |